Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-negative Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableActive Not RecruitingNCT02455791
What this trial is testing

Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 43
Testing effectiveness (Phase 2)Study completedNCT02403271
What this trial is testing

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerBreast CancerPancreatic Cancer
Pharmacyclics LLC. 124
Testing effectiveness (Phase 2)Study completedNCT02481050
What this trial is testing

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Eisai Inc. 58
Testing effectiveness (Phase 2)Looking for participantsNCT07025889
What this trial is testing

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

Who this might be right for
Gastric Cancer
Ruijin Hospital 55
Not applicableLooking for participantsNCT07067138
What this trial is testing

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

Who this might be right for
Breast CancerBreast CarcinomaCancer of the Breast+1 more
National Cancer Institute (NCI) 175
Testing effectiveness (Phase 2)Ended earlyNCT03952325
What this trial is testing

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 294
Testing effectiveness (Phase 2)Looking for participantsNCT07191717
What this trial is testing

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+3 more
Jonsson Comprehensive Cancer Center 42
Early research (Phase 1)Looking for participantsNCT07369505
What this trial is testing

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Who this might be right for
Breast Cancer MetastaticRenal Cell Carcinoma (RCC)Neuroendocrine Tumors+2 more
SAPU NANO (US) LLC 27
Not applicableUnknownNCT06156761
What this trial is testing

Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 24
Testing effectiveness (Phase 2)UnknownNCT05721651
What this trial is testing

Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study

Who this might be right for
Gastric Cancer
Wu Jun 60
Testing effectiveness (Phase 2)UnknownNCT01709370
What this trial is testing

Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women

Who this might be right for
ER Positive, HER2 Negative Breast Cancer
Organisation for Oncology and Translational Research 45
Testing effectiveness (Phase 2)UnknownNCT05512780
What this trial is testing

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

Who this might be right for
Solid Tumor
Hebei Medical University Fourth Hospital 30
Not applicableUnknownNCT06174259
What this trial is testing

Influence of Intermittent Fasting on Locally Advanced Breast Cancer Patients

Who this might be right for
Locally Advanced Breast CancerIntermittent Fasting
Menoufia University 66
Testing effectiveness (Phase 2)Active Not RecruitingNCT04561362
What this trial is testing

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Who this might be right for
Urinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative Neoplasms+5 more
BicycleTx Limited 329
Not applicableActive Not RecruitingNCT07541703
What this trial is testing

Independent, External, Blinded Retrospective Validation of an AI-based Prognostic Assay in ER-Positive/HER2-Negative Early Breast Cancer

Who this might be right for
Breast CancerEarly Breast CancerER-Positive HER2-Negative Breast Cancer
Spotlight Medical 2,200
Large-scale testing (Phase 3)UnknownNCT00532727
What this trial is testing

Triple Negative Breast Cancer Trial

Who this might be right for
Breast Cancer
Institute of Cancer Research, United Kingdom 400
Testing effectiveness (Phase 2)UnknownNCT03906669
What this trial is testing

A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.

Who this might be right for
Early-stage Breast CancerHormone Receptor Positive Tumor
St Vincent's Hospital 200
Large-scale testing (Phase 3)UnknownNCT01622361
What this trial is testing

Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer

Who this might be right for
Breast Cancer
Asan Medical Center 290
Testing effectiveness (Phase 2)Study completedNCT02988986
What this trial is testing

TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer

Who this might be right for
Estrogen Receptor Positive Breast Cancer
The Methodist Hospital Research Institute 28
Large-scale testing (Phase 3)Looking for participantsNCT07541079
What this trial is testing

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

Who this might be right for
Early Breast Cancer
Genentech, Inc. 300
Next Page